Citations

Clear

2236 citation(s) found for "Ju, Angela".

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement
Xiao, Alexander , Zanwar, Saurabh , Lin, Yi, Kapoor, Prashant , Abdallah, Nadine , Baudi, Francis, Dingli, David, Gertz, Morie A. , Gonsalves, Wilson I, Hayman, Suzanne R. , Kourelis, Taxiarchis , Tan, Melinda SY, Warsame, Rahma , Rajkumar, S Vincent, Kumar, Shaji , Dingli, David , Buadi, Francis K. , Lin, Yi , Lin, Yi , Buadi, Francis K , Binder, Moritz , Dispenzieri, Angela , Dingli, David , Gertz, Morie A , Gonsalves, Wilson , Kourelis, Taxiarchis , Leung, Nelson , Muchtar, E , Siddiqui, Mustaqeem A , Tan, Melinda , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Xiao, Alexander H , Binder, Moritz , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Muchtar, Eli , Siddiqui, Mustaqeem , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: 10 | Issue: 17 | Pages: 5828-5833

10.1182/bloodadvances.2026020668 | PMID 42348786 Get It

Abstract Extramedullary disease (EMD) is increasingly recognized in relapsed/refractory multiple myeloma (MM), with central nervous system involvement (CNS-MM) representing a rare but highly aggressive manifestation associated with dismal outcomes. Data on its incidence and optimal management, particularly in the era of cellular and bispecific therapies, remain limited. We conducted a retrospective analysis of patients with MM with pathology-confirmed EMD treated at our institution between January 2000 and December 2023. CNS-MM was defined by parenchymal or leptomeningeal involvement. Clinical features, cytogenetics, treatments, and outcomes were analyzed, with predictors of CNS involvement evaluated among patients with EMD. Among 304 patients with EMD, 20 (6.5%) had CNS-MM. CNS involvement occurred a median of 19.2 months after MM diagnosis, though 15% presented at diagnosis. CNS-MM was strongly associated with high-risk cytogenetics (odds ratio [OR], 3.7) and additional visceral EMD (OR, 4.6). Median overall survival (OS) from CNS-MM diagnosis was 4.2 months. Outcomes were significantly improved in patients receiving chimeric antigen receptor T-cell therapy or bispecific antibodies, with a median OS of 19.2 months vs 1.2 months in those who did not receive immune effector therapies. Intrathecal (IT) chemotherapy demonstrated limited and transient benefit. In conclusion, CNS-MM is an aggressive complication enriched in high-risk, multifocal EMD with extremely poor prognosis. Cellular and bispecific therapies show promising activity and may meaningfully improve survival, whereas IT therapy appears to have limited efficacy. Prospective studies are needed to define optimal treatment strategies for CNS-MM.
27Novel blood metabolomic tests for the diagnosis of Primary Sclerosing Cholangitis and associated Cholangiocarcinoma
Catanzaro, Elisa , Echebarria, Anne, Milkiewicz, Piotr, Carbone, Marco, Milkiewicz, Malgorzata, Fowsiyo, Ahmed, Elgozair, Mohamad, Casta, Adelaida La, Jimenez-Aguero, Raul, Perugorria, María J. , Cristoferi, Laura, Hov, Johannes R, Schramm, Christoph, Crespo, Gonzalo, Arrese, Marco, Bustamante, Javier, Dill, Michael , Balderramo, Domingo, Bujanda, L. , Roberts, Lewis, Karlsen, Tom Hemming, Folseraas, Trine , Lapitz, Ainhoa , Martínez‐Arranz, Ibon , Milkiewicz, Piotr , Carbone, Marco , Alonso, Cristina , Montilla, Alejandro , Milkiewicz, Malgorzata, Ahmed, Fowsiyo , Elgozair, Mohamad, Izquierdo‐Sánchez, Laura , Jiménez-Aguero, Raul, Cristoferi, Laura , Hov, Johannes R. , Schramm, Christoph , Crespo, Gonzalo , Arrese, Marco , Chahuán, Javier , Bustamante, Javier, Lamarca, Angela , Karlsen, Tom Hemming, Rodrigues, Pedro M. , Bañales, Jesús M.

Mayo Clinic

The Oncologist | June 23, 2026 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/oncolo/oyag205.028 Get It

Abstract Background and Aims Primary sclerosing cholangitis (PSC) increases the risk of developing cholangiocarcinoma (CCA), which is the leading cause of premature death in these patients. Current diagnostic methods for early detection of either condition remain largely suboptimal. This study investigates serum metabolites as potential non-invasive diagnostic biomarkers. Methods This multicenter international study analyzed 459 serum samples from 13 international centers, including patients with PSC (n = 216), PSC who developed CCA during follow-up (PSC to CCA; n = 24), PSC with concomitant CCA (PSC-CCA; n = 88), ulcerative colitis (UC; n = 14), and healthy individuals (n = 79). Serum metabolomics was evaluated by ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) and the accuracy of the single candidate metabolite biomarkers was further assessed. Machine learning was used to generate the best diagnostic and predictive algorithms. Results Fifty-two serum metabolites were identified as markers of PSC, independent of age, biological sex, cirrhosis, UC, or ursodeoxycholic acid (UDCA) treatment. A diagnostic model based on only six lipids distinguished PSC patients from healthy controls with high accuracy (AUC 0.952 discovery, 0.918 validation), independently of the levels of transaminases or cholestasis markers (i.e., GGT, AP, bilirubin) in blood. Subgroup analyses were performed in PSC patients with and without inflammatory bowel disease (IBD), confirming the model’s consistent performance across both subgroups when compared with their respective control groups – UC and healthy controls (AUC 0.959 and 0.939, respectively). The PSC model also confirmed its diagnostic performance in patients with established PSC-CCA or progression to CCA within 2 years, when compared to UC and healthy controls, showing AUC values ranging from 0.911 to 0.976. Additionally, 20 metabolites were significantly altered in PSC patients with CCA (PSC-CCA), regardless of demographics, cirrhosis, UDCA treatment, IBD status, or CCA subtype, and independently of serum transaminases and cholestatic markers levels. A model incorporating six lipids accurately identified PSC-CCA cases compared to PSC patients (AUC = 0.912 discovery; 0.896 validation), showing excellent performance in early-stage tumor detection (AUC 0.921) and outperforming CA19-9 (AUC 0.708). Importantly, the model retained high accuracy even in CCA patients with low CA19-9 levels (AUC 0.905) and in PSC patients who developed CCA within a year of clinical diagnosis (AUC 0.792). Conclusion The PSC and PSC-CCA blood tests provide a non-invasive approach for diagnosing PSC and PSC-CCA, addressing an important need in this population. Their integration into clinical practice could enhance risk stratification, early detection, personalized surveillance, and treatment decision-making in PSC patients.
Authorship and citation trends in dementia research: A path to equitable career development for scientists
Viswanathan, Jayalakshmi , Thakur, Lokendra S., Sawan, Mouna, Gomez‐Arboledas, Angela, Moreno‐Gonzalez, Ines, Shaaban, C, Milani, Sadaf A., Wuestefeld, Anika , Govindarajan, Sindhuja T., Carello‐Collar, Giovanna, Shreshta, Hom L., Kenowsky, Sunnie , Suemoto, Claudia K., Stites, Shana D., Karamacoska, Diana , Sawan, Mouna J. , Gómez-Arboledas, Ángela , Moreno‐González, Inés , Shaaban, C. Elizabeth , Milani, Sadaf Arefi , Milinkeviciute, Giedre , Loi, Samantha M. , Govindarajan, Sindhuja Tirumalai , Low, Audrey , Carello‐Collar, Giovanna , Suemoto, Cláudia Kimie , Mielke, Michelle M. , Stites, Shana D.

Mayo Clinic

Alzheimer's & Dementia | June 19, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71597 | PMID 42316439 Get It

Abstract INTRODUCTION Women are increasingly entering the dementia research workforce, but they frequently fail to attain senior leadership positions in academia. Discrepancies in academic research outputs were investigated to guide equity‐focused policy recommendations. METHODS Bibliometrics was conducted on 400,482 original research articles (2003–2022) followed by surveying the AD/ADRD research community, to quantitatively and qualitatively evaluate discrepancies in publication and authorship trends. In addition, an unsupervised learning algorithm was developed to analyze underlying relationships between author groups. RESULTS Male author gender was consistently predictive of better publication and citation metrics across all bibliometrics outcomes, with senior male authors outperforming all other subgroups and fewer senior female authors in most research areas. Female survey respondents reported more barriers, but comparable productivity and citation strategies as male authors. DISCUSSION Multi‐pronged approaches by stakeholders across institutions, funders, and journals are necessary to provide career support for early‐career scientists working to transition to senior research roles.
Survival Trends in Waldenström Macroglobulinemia and Comparison of Outcomes with the General US Population
Zanwar, Saurabh , Khan, Muhammad Azeem , Gaur, Gunjan , Abeykoon, Jithma P. , Gertz, Morie A. , Kumar, Shaji , King, Rebecca, Habermann, Thomas M. , Go, Ronald S. , Abdallah, Nadine , Thanarajasingam, Gita , Thompson, CM, Nowakowski, Grzegorz S. , Dasari, Surendra , Novak, Joseph, Warsame, R., Ansell, Stephen M. , Kapoor, Prashant , Go, Ronald S , Gertz, Morie A , Habermann, Thomas , Paludo, Jonas , Cook, Joselle , Buadi, Francis K. , Dispenzieri, Angela , Gonsalves, Wilson I. , Dingli, David , Muchtar, Eli , Greipp, Patricia T. , Novak, Joseph P. , Warsame, Rahma , Witzig, Thomas E. , Rajkumar, S. Vincent

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9904019/v1 Get It

Abstract Therapeutic options for Waldenström macroglobulinemia (WM) have expanded but improvements in overall-survival (OS) are difficult to interpret due to competing non–WM mortality. We conducted a large single-center retrospective study of 1,020 patients with WM to evaluate survival trends. Patients were stratified by era of active WM diagnosis using a two-era model (1996–2005 and post-2005) and a four-era model (pre-2001, 2001–2007, 2008–2013, and post-2013). OS did not differ significantly across eras in the overall cohort (p = 0.64 and p = 0.86 for the two- and four-era models). However, among patients aged < 65 years at the time of active WM diagnosis in the 2-era model, OS improved in the post-2006 era (median 18.8 vs 14.1 years, p = 0.018). Cause-specific-survival (CSS) improved across all eras, increasing from 15.6 years in 1996–2005 to 18.9 years post-2006 (p < 0.0001), and from 13.7 years pre-2001 to not reached in later periods in the four-era model (p < 0.0001). Competing-risk-analysis (CRA) demonstrated a reduction in WM-related mortality over time (p < 0.001). However, excess mortality persisted, with a standardized mortality ratio (SMR) of 2.79 (p < 0.001) among patients < 65 years compared with a matched U.S. population. Our findings highlight improvements in WM-specific survival, while gains in OS are observed in younger patients.
Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS)
Andrieu, Sandrine, Bradshaw, Angela, Carmona, Ralph C., Iwatsubo, Takeshi, Hansson, Oskar, Jr, Clifford R Jack, Jicha, Gregory A, McDade, DO Eric, Mummery, Catherine J, Petersen, Ronald C, Robinson, Shelagh, Schneider, Julie A., Shellcross, Lenny, Smith, Amanda G, Snyder, Heather M. , Tapply, Beth, Teunissen, Charlotte, Flier, Wiesje M. van der, Vellas, Bruno, Williamson, Jeff D. , Wilcock, Donna, Carrillo, Maria C., Amouyel, Philippe , Andrieu, Sandrine , Bradshaw, Angela C. , Dumont, Magali , Grinberg, Lea T. , Iwatsubo, Takeshi , Hansson, Oskar , Jack, Clifford R. , Jicha, Gregory A. , Mahinrad, Simin , McDade, Eric , Mummery, Catherine J. , Petersen, Ronald C. , Schneider, Julie A. , Teunissen, Charlotte E. , Flier, Wiesje M. van der , Vellas, Bruno , Wallon, David , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | June 16, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71536 | PMID 42298289 Get It

Abstract Since 2016, the Alzheimer's Association and the Fondation Alzheimer have hosted Global Alzheimer's Leadership Series (GoALS) global think tanks, with world‐leading experts for innovative discussions to advance Alzheimer's disease (AD) research and care. The second GoALS think tank, held in June 2024 in Paris, focused on the relationship between biological changes and clinical manifestations of AD in the context of the evolving therapeutic landscape. Discussions spanned real‐world experiences of providers, patients, and their families, theoretical considerations, and health system challenges. The lived experience perspective was central to these discussions. The importance of shared decision‐making, clear and transparent communication, and the need for real‐world data to holistically support patients during their experiences were highlighted. This manuscript shares key insights from both the think tank meeting in Paris and a featured research session at the 2024 Alzheimer's Association International Conference that expanded the discussion themes for broader dissemination with the community.
Frequency of White Matter Hyperintensities Across Neurodegenerative Syndromes Compared to Cognitively Unimpaired Individuals (P7-12.013)
Bermudez, Camilo , Fought, Angela, Hofrenning, Ekaterina, Kantarci, Kejal, Jack, Clifford, Boeve, Bradley, Knopman, David, Ramanan, Vijay, McCarter, SJ, Petersen, Ronald, Vemuri, Prashanthi, Graff-Radford, Jonathan, Hofrenning, Ekaterina I. , Kantarci, Kejal , Jack, Clifford, Boeve, Bradley, Jones, David, Knopman, David S. , Botha, Hugo , Ramanan, Vijay K. , Petersen, Ronald, Vemuri, Prashanthi , Graff‐Radford, Jonathan

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215057 Get It

Safety and efficacy of flowable microfibrillar collagen hemostat in an ovine model of lumbar laminectomy and open durotomy compared with the gelatin-thrombin hemostatic matrix and control
Rossi, Amie, Bradbury, Kasia , Abode-Iyamah, Kingsley, Bohnen, Angela, Gagne, Darcy, Abode-Iyamah, Kingsley , Bohnen, Angela M. , Gagne, Darcy H.

Mayo Clinic

Frontiers in Surgery | June 9, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fsurg.2026.1760993 | PMID 42344574 Get It

Background Effective hemostasis in spinal surgery is critical, especially near sensitive structures such as the spinal cord and dorsal root ganglia. Flowable hemostatic agents offer targeted control in irregular, hard-to-reach areas. This study evaluates the safety and efficacy of flowable collagen hemostat (FC) in an ovine lumbar laminectomy model with open durotomy by making a direct comparison with the gelatin hemostatic matrix with thrombin (GM) and a no-treatment control (Sham). Methods Fifty-four Polypay sheep (27 F, 27 M) underwent lumbar laminectomy and open durotomy and then received FC, GM, or no treatment ( n = 18/group). Hemostasis was assessed at 3 min postapplication without tamponade. Neurological examinations were performed at periodic intervals, and tissues were collected on days 7, 45, and 120 for a histological analysis. Results Hemostasis was achieved in 100% of FC-treated sites, 94.4% of GM, and 72.2% of Sham. Sham-treated animals exhibited more severe and prolonged neurological deficits compared with those treated with FC or GM. Inflammation decreased significantly across all groups, from mild/moderate on day 7 to minimal on day 45, and was barely detectable by day 120. FC was associated with favorable histological responses in both intradural and extradural spinal tissues, comparable to GM and Sham. Conclusion Flowable collagen hemostat was safe and effective when applied directly to the spinal cord and surrounding neurological tissues during laminectomy with open durotomy. Its performance was comparable to that of the gelatin hemostatic matrix with thrombin in terms of hemostatic efficacy and histological outcomes, with both agents demonstrating superior neurological recovery compared with the untreated Sham group.
Reflections on rural community characteristics by an outreach, recruitment, and engagement team
Vassilaki, Maria , Smith, Steven M. , Loftin, Tasha M. , Mohamed, Essa A. , Rethemeier, Nick , Coburn, Ryan P , Graff‐Radford, Jonathan , Petersen, Ronald C. , Boeve, Bradley F. , Lunde, Angela , Lunde, Angela M , Boeve, Brad , Coburn, Ryan P

Mayo Clinic

Journal of Alzheimer’s Disease | June 9, 2026 | Volume: 112 | Issue: 3 | Pages: 1175-1181

10.1177/13872877261454612 | PMID 42261694 Get It

Rural populations are underrepresented in cognitive impairment research and have limited resources for education about brain and cognitive health, Alzheimer's disease and related dementias, or caregiving. As our Outreach, Recruitment, and Engagement team aimed to expand activities into more rural communities, we also wanted to better understand the characteristics of the communities surrounding our center and gain insight into the social exposome of the areas. The goal of the manuscript is to reflect on our experience and share measures that were useful in this effort, which can be further enriched and adjusted by other outreach teams.